CP 001 - YIRUI Pharmaceutical Technology
Alternative Names: CP-001 - YIRUI Pharmaceutical TechnologyLatest Information Update: 14 Nov 2024
Price :
$50 *
At a glance
- Originator Unknown
- Developer Unknown; YIRUI Pharmaceutical Technology
- Class Erectile dysfunction therapies; Small molecules
- Mechanism of Action Nitric oxide synthase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Erectile dysfunction
Most Recent Events
- 21 Oct 2024 YIRUI Pharmaceutical Technology expects submission of new drug application in 2027 or 2028 (Topical) (YIRUI Pharmaceutical Technology pipeline, October 2024)
- 17 Oct 2024 Preclinical trials in Erectile dysfunction in China (Topical) (YIRUI Pharmaceutical Technology pipeline, October 2024)
- 30 Jun 2024 YIRUI Pharmaceutical Technology plans phase I trial in Erectile dysfunction in first half of 2024 outside China (Topical) (YIRUI Pharmaceutical Technology pipeline, October 2024)